Guarnaccia S, Pais V, Grous J, Spirito N
Division of Urology, St. Elizabeth Hospital, Boston, Massachusetts.
J Urol. 1991 Jan;145(1):140-1. doi: 10.1016/s0022-5347(17)38271-x.
Adenocarcinoma of the urachus is a rare genitourinary tumor with a poor prognosis. The treatment of choice is en bloc surgical resection, although combination therapy with surgery and chemotherapy has been used with mixed results. We describe a 69-year-old woman with adenocarcinoma of the urachus and elevated serum levels of CA 125 tumor marker. She was treated with resection plus 5-fluorouracil, doxorubicin and mitomycin, alternating with platinum-based chemotherapy. The serum CA 125 level decreased precipitously after the operation and became normal after 2 months of chemotherapy. The patient remained free of disease 1 year postoperatively. Serum CA 125 may be a useful tumor marker for urachal carcinoma and adjuvant chemotherapy may be effective in treating the disease.
脐尿管腺癌是一种罕见的泌尿生殖系统肿瘤,预后较差。尽管手术联合化疗的综合治疗效果不一,但首选治疗方法仍是整块手术切除。我们报告一例69岁患有脐尿管腺癌且血清CA 125肿瘤标志物水平升高的女性患者。她接受了手术切除加5-氟尿嘧啶、阿霉素和丝裂霉素治疗,并与铂类化疗交替进行。术后血清CA 125水平急剧下降,化疗2个月后恢复正常。患者术后1年无疾病复发。血清CA 125可能是脐尿管癌的一种有用的肿瘤标志物,辅助化疗可能对治疗该疾病有效。